Flagship Pioneering launched Expedition Medicines with a $50 million commitment to build an AI-driven platform focused on covalent small-molecule drug discovery, the firm said. Expedition emerges from Flagship incubation and plans to apply generative chemistry, quantum-informed models and chemoproteomics to targets considered difficult to drug. The new company has already announced a multi-target research collaboration with Pfizer and intends to prioritize oncology and immune-related programs. Expedition’s launch underscores the continued wave of venture-backed platform companies marrying AI, quantum chemistry and large-scale experimental data to accelerate small‑molecule discovery.